
簡要描述:Benfotiamine 22457-89-2Benfotiamine, the lipid-soluble thiamine derivative used as a treatment for diabetic neuropathy,
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細介紹
| 品牌 | absin | CAS | 22457-89-2 |
|---|---|---|---|
| 分子式 | C19H23N4O6PS | 純度 | >98% |
| 分子量 | 466.46 | 貨號 | abs47027512 |
| 規(guī)格 | 500mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used as a treatment for diabetic neuropa | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Benfotiamine 22457-89-2
| 產(chǎn)品描述 | |
| 描述 | Benfotiamine, the lipid-soluble thiamine derivative used as a treatment for diabetic neuropathy, can inhibit three major pathways(the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)?protein kinase C (PKC) pathway)of hyperglycemic damage and prevent experimental diabetic retinopathy. Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1) for treating sciatica and other painful nerve conditions. More effective at increasing thiamin levels in blood and tissues than water-soluble salts like the previous vitamin B1. |
| 純度 | >98% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 苯磷硫胺;S-Benzoylthiamine O-monophosphate |
| 外觀 | 白色結(jié)晶性粉未 |
| 可溶性/溶解性 | DMSO : ≥ 50 mg/mL (107.19 mM) H2O : 0.67 mg/mL (1.44 mM; Need ultrasonic) |
| 生物活性 | |
| In vitro(體外研究) | Benfotiamine improves the expression of endothelial cell markers in EPCs, restores eNOS levels, and recovers the ability of EPCs to participate in angiogenic processes. It is able to dampen glucose toxicity effects on endothelial progenitors. Benfotiamine possesses antitumor activity against leukemia cells. In a panel of nine myeloid leukemia cell lines benfotiamine impairs the viability of HL-60, NB4, K562 and KG1 cells and also inhibits the growing of primary leukemic blasts. The antitumor activity of benfotiamine is not mediated by apoptosis, necrosis or autophagy, but rather occurs though paraptosis cell death induction. Benfotiamine inhibits the activity of constitutively active ERK1/2 and concomitantly increases the phosphorylation of JNK1/2 kinase in leukemic cells. In addition, benfotiamine induces the down regulation of the cell cycle regulator CDK3 which results in G1 cell cycle arrest in the sensitive leukemic cells. |
| In vivo(體內(nèi)研究) | Benfotiamine might exert vascular and renal benefits by modulating mechanisms independent or downstream of ROS formation. Benfotiamine aids the post-ischaemic healing of diabetic animals via PKB/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
